Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial

Ahmed M Al Rajeh, Yousef Saad Aldabayan, Abdulelah Aldhahir, Elisha Pickett, Shumonta Quaderi, Jaber S Alqahtani, Swapna Mandal, Marc Ci Lipman, John R Hurst, Ahmed M Al Rajeh, Yousef Saad Aldabayan, Abdulelah Aldhahir, Elisha Pickett, Shumonta Quaderi, Jaber S Alqahtani, Swapna Mandal, Marc Ci Lipman, John R Hurst

Abstract

Background: Earlier detection of chronic obstructive pulmonary disease (COPD) exacerbations may facilitate more rapid treatment with reduced risk of hospitalization. Changes in pulse oximetry may permit early detection of exacerbations. We hypothesized that overnight pulse oximetry would be superior to once-daily monitoring for the early detection of exacerbations.

Objective: This study aims to evaluate whether measuring changes in heart rate and oxygen saturation overnight is superior to once-daily monitoring of both parameters and to assess symptom changes in facilitating earlier detection of COPD exacerbations.

Methods: A total of 83 patients with COPD were randomized to once-daily or overnight pulse oximetry. Both groups completed the COPD assessment test questionnaire daily. The baseline mean and SD for each pulse oximetry variable were calculated from 14 days of stable monitoring. Changes in exacerbation were expressed as Z scores from this baseline.

Results: The mean age of the patients was 70.6 (SD 8.1) years, 52% (43/83) were female, and the mean FEV1 was 53.0% (SD 18.5%) predicted. Of the 83 patients, 27 experienced an exacerbation. Symptoms were significantly elevated above baseline from 5 days before to 12 days after treatment initiation. Day-to-day variation in pulse oximetry during the stable state was significantly less in the overnight group than in the once-daily group. There were greater relative changes at exacerbation in heart rate than oxygen saturation. An overnight composite score of change in heart rate and oxygen saturation changed significantly from 7 days before initiation of treatment for exacerbation and had a positive predictive value for exacerbation of 91.2%. However, this was not statistically better than examining changes in symptoms alone.

Conclusions: Overnight pulse oximetry permits earlier detection of COPD exacerbations compared with once-daily monitoring. Monitoring physiological variables was not superior to monitoring symptoms, and the latter would be a simpler approach, except where there is a need for objective verification of exacerbations.

Trial registration: ClinicalTrials.gov NCT03003702; https://ichgcp.net/clinical-trials-registry/NCT03003702.

Keywords: CAT; chronic obstructive pulmonary disease; exacerbations; heart rate; oxygen saturation; telehealth.

Conflict of interest statement

Conflicts of Interest: None declared.

©Ahmed M Al Rajeh, Yousef Saad Aldabayan, Abdulelah Aldhahir, Elisha Pickett, Shumonta Quaderi, Jaber S Alqahtani, Swapna Mandal, Marc CI Lipman, John R Hurst. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 13.11.2020.

Figures

Figure 1
Figure 1
CONSORT (Consolidated Standards of Reporting Trials) flow diagram. OSA: obstructive sleep apnea; O2: oxygen.
Figure 2
Figure 2
Chronic obstructive pulmonary disease assessment test score (green line) and peak expiratory flow (blue line) changes pre and post exacerbation in 27 patients with chronic obstructive pulmonary disease. The y-axis represents Z score relative to the patient’s baseline mean. The x-axis represents the time expressed in days. Day −15 is the mean of the stable period, days −14 to −1 is the preexacerbation period, day 0 is the day of initiation of treatment for exacerbation, and days 1 to 13 is the postexacerbation recovery period. The red lines represent the threshold limits of ±1.96 SD.
Figure 3
Figure 3
Heart rate changes pre and post exacerbation for the 27 patients with chronic obstructive pulmonary disease. The y-axis represents the Z score relative to the patient’s baseline mean. The x-axis represents the time expressed in days. Day −15 is the mean of the stable period, days −14 to −1 is the preexacerbation period, day 0 is the day of initiation of treatment for exacerbation, and days 1 to 13 is the postexacerbation recovery. The red line represents the threshold limit of +1.96 SD. The once-daily group is represented by the green line and the overnight group by the blue line.
Figure 4
Figure 4
Oxygen saturation changes pre and post exacerbation for the 27 patients with chronic obstructive pulmonary disease. The y-axis represents the Z score relative to the patient’s baseline mean. The x-axis represents the time expressed in days. Day −15 is the mean of the stable period, days −14 to −1 is the preexacerbation period, day 0 is the day of initiation of treatment for exacerbation, and days 1 to 13 is the postexacerbation recovery. The red line represents the threshold limit of +1.96 SD. The once-daily group is represented by the green line and the overnight group by the blue line.
Figure 5
Figure 5
Composite pulse oximetry score changes pre and post exacerbation for the 27 patients with chronic obstructive pulmonary disease. The y-axis represents the Z score relative to the patient’s baseline mean. The x-axis represents the time expressed in days. Day −15 is the mean of the stable period, days −14 to −1 is the preexacerbation period, day 0 is the day of initiation of treatment for exacerbation, and days 1 to 13 is the postexacerbation recovery. The red line represents the threshold limit of +1.96 SD. The once-daily group is represented by the green line and the overnight group by the blue line.

References

    1. Burden of COPD. World Health Organization. [2019-01-29].
    1. World Health Statistics. World Health Organization. 2008. [2019-01-18]. .
    1. Lee S, Huang M, Kang J, Lin C, Park MJ, Oh Y, Kwon N, Jones PW, Sajkov D, Investigators of the Predictive Ability of CAT in Acute Exacerbations of COPD (PACE) Study The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respir Med. 2014 Apr;108(4):600–8. doi: 10.1016/j.rmed.2013.12.014.
    1. Chronic Obstructive Pulmonary Disease (COPD) Facts Sheet. World Health Organization. 2017. Dec 01, [2019-01-29].
    1. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Jun 15;169(12):1298–303. doi: 10.1164/rccm.200310-1443OC.
    1. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608–13. doi: 10.1164/ajrccm.161.5.9908022.
    1. Al Rajeh A, Hurst J. Monitoring of physiological parameters to predict exacerbations of chronic obstructive pulmonary disease (COPD): a systematic review. J Clin Med. 2016 Nov 25;5(12):-. doi: 10.3390/jcm5120108.
    1. Struik FM, Sprooten RT, Kerstjens HA, Bladder G, Zijnen M, Asin J, Cobben NA, Vonk JM, Wijkstra PJ. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax. 2014 Sep;69(9):826–34. doi: 10.1136/thoraxjnl-2014-205126.
    1. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Patel AR, Wedzicha JA. Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med. 2010 Oct 20;10:52. doi: 10.1186/1471-2466-10-52.
    1. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540–5. doi: 10.1093/sleep/14.6.540.
    1. Nagappa M, Liao P, Wong J, Auckley D, Ramachandran SK, Memtsoudis S, Mokhlesi B, Chung F. Validation of the STOP-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLoS One. 2015;10(12):e0143697. doi: 10.1371/journal.pone.0143697.
    1. Operator’s Manual. Nonin Medical: Pulse and Regional Oximeters, Capnographs. [2020-04-01]. .
    1. GO2 Model 9570 Fingertip Pulse Oximeter. Nonin Medical: Pulse and Regional Oximeters, Capnographs. 2019. [2020-04-01]. .
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128–38. doi: 10.1056/NEJMoa0909883.
    1. Wardini R, Dajczman E, Yang N, Baltzan M, Préfontaine D, Stathatos M, Marciano H, Watson S, Wolkove N. Using a virtual game system to innovate pulmonary rehabilitation: safety, adherence and enjoyment in severe chronic obstructive pulmonary disease. Can Respir J. 2013;20(5):357–61. doi: 10.1155/2013/563861. doi: 10.1155/2013/563861.
    1. The Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung. 2020. [2020-09-18]. .
    1. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012 Mar;67(3):238–43. doi: 10.1136/thoraxjnl-2011-200768.
    1. Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014 Mar;2(3):195–203. doi: 10.1016/S2213-2600(14)70001-3.
    1. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1218–24. doi: 10.1164/rccm.201110-1843OC.
    1. Murata GH, Lium DJ, Busby HK, Kapsner CO. Precision and accuracy of self-measured peak expiratory flow rates in chronic obstructive pulmonary disease. South Med J. 1998 Oct;91(10):919–24. doi: 10.1097/00007611-199810000-00005.
    1. Emerman CL, Cydulka RK. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1996 Feb;27(2):159–63. doi: 10.1016/s0196-0644(96)70317-7.
    1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–22. doi: 10.1164/ajrccm.157.5.9709032.
    1. Burton C, Pinnock H, McKinstry B. Changes in telemonitored physiological variables and symptoms prior to exacerbations of chronic obstructive pulmonary disease. J Telemed Telecare. 2015 Jan;21(1):29–36. doi: 10.1177/1357633X14562733.
    1. Martín-Lesende I, Orruño E, Bilbao A, Vergara I, Cairo MC, Bayón JC, Reviriego E, Romo MI, Larrañaga J, Asua J, Abad R, Recalde E. Impact of telemonitoring home care patients with heart failure or chronic lung disease from primary care on healthcare resource use (the TELBIL study randomised controlled trial) BMC Health Serv Res. 2013 Mar 28;13:118. doi: 10.1186/1472-6963-13-118.
    1. Pedone C, Chiurco D, Scarlata S, Incalzi RA. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv Res. 2013 Mar 6;13:82. doi: 10.1186/1472-6963-13-82.
    1. Al Rajeh A, Steiner MC, Aldabayan Y, Aldhahir A, Pickett E, Quaderi S, Hurst JR. Use, utility and methods of telehealth for patients with COPD in England and Wales: a healthcare provider survey. BMJ Open Respir Res. 2019;6(1):e000345. doi: 10.1136/bmjresp-2018-000345.
    1. Frühauf J, Schwantzer G, Ambros-Rudolph CM, Weger W, Ahlgrimm-Siess V, Salmhofer W, Hofmann-Wellenhof R. Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis. Australas J Dermatol. 2012 Feb;53(1):41–6. doi: 10.1111/j.1440-0960.2011.00852.x.

Source: PubMed

3
Abonner